Shamis & Gentile, P.A. is investigating claims on behalf of investors of Align Technology Inc. (“Align Technology” or the “Company”) (ALGN). Impacted investors are advised to contact the firm now.
The investigation focuses on whether Align Technology made materially false and misleading statements or omitted material information regarding its business prospects, demand trends and financial guidance.
Align Technology is a medical device company that offers Invisalign, an orthodontic treatment, that uses removable clear aligners to straighten teeth. On July 30, 2025, after the market closed, Align Technology filed an 8-K and press release revealing that Q2 demand had been weaker than previously portrayed, with clear aligner shipments growing only 0.3% sequentially—far short of the “mid-single-digit” volume increases previously touted. The Company reported Q2 revenue of $1.012 billion, missing both its own guidance and analyst expectations.
Align Technology also announced a significant reduction in Q3 2025 revenue guidance to $965–$985 million, cut full-year clear aligner volume growth expectations to “low-single digits” and disclosed plans to incur $150–$170 million in restructuring and write-down charges in the second half of 2025.
On this news, Align Technology’s stock price fell $68.06 per share, or 36.86%, to close at $136.14 per share on July 30, 2025, erasing more than $4 billion in market capitalization.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters including class actions, mass torts and mass arbitrations.
Attorney advertising. Prior results do not guarantee similar outcomes.
